Шетелдегі Онкологтың онлайн консультациясы бойынша дәрігерлер — 4 беті

Дәрігер кеуде қуысының қатерлі ісіктерін басқаруға жауапты және онкология бөлімінде кеуде рагы бойынша сынақтарды қадағалайды. Олардың зерттеулері аурудың ерте кезеңдерінде химиотерапияны оңтайландыруға, жаңа терапияларды бағалауға, фармакогеномдық тәсілдерді зерттеуге, өкпе рагы үшін иммунотерапияны біріктіруге және тирозинкиназа ингибиторларына төзімділік механизмдерін зерттеуге бағытталған.<\/p>

UAB-дан медициналық дәрежесі және медициналық онкология бойынша PhD дәрежесі бар дәрігер ESMO, ASCO және IASLC сияқты бірнеше беделді онкологиялық қоғамдардың мүшесі болып табылады. Олар кеуде қуысының қатерлі ісіктері туралы көптеген рецензияланған мақалалар мен кітап тарауларын жариялады және UAB және UVicc-UCC-де оқытушылық қызметтер атқарды.<\/p>

Dr. Hasan Mutlu is a medical oncologist at Medical Park Antalya Hospital Complex. He specializes in immunotherapy, targeted cancer therapies, and genetic research in cancer treatment. Dr. Mutlu received his medical degree from Hacettepe University. He holds the title of Professor of Medicine. Dr. Mutlu focuses on organ tumor diagnosis and chemotherapy.

• Specializes in both medical and pediatric oncology cases.
• Treats complex conditions including neuroblastoma, Wilms tumor, and Ewing's sarcoma.
• Performs biological therapies and stays active in next-generation genetic research.
• Works at the Mediterranean region’s largest private hospital with PET-CT and LINAC technology.

Дәрігер 33 жылдық тәжірибесі бар медициналық онколог және радиотерапевт, онкология және радиотерапия саласында маманданған. Ол Иерусалимдегі (Израиль) Хадасса университеттік ауруханасын бітірген және онкология мен радиотерапия саласында біліктілігі бар.<\/p>

Қазіргі уақытта ол Асқазан-ішек қатерлі ісік орталығының басшысы болып табылады, сондай-ақ Хадасса университеттік ауруханасының онкология бөлімінде аға дәрігер болып қызмет етеді. Ол онкология және радиотерапия саласындағы сертификаттау емтихандарын тапсырды және Израиль клиникалық онкология қоғамы мен Израиль қатерлі ісік қауымдастығы сияқты бірнеше кәсіби қоғамдардың мүшесі болып табылады.<\/p>

Dr. Gul Alco is a radiation oncologist and Professor at Medipol Acibadem District Hospital in Istanbul. She excels in treating complex cases, including stage 4 lung and liver cancers. Dr. Alco utilizes the CyberKnife and Da Vinci robotic systems for precise tumor targeting. She works at a JCI-accredited facility known for its high safety standards.

• Specializes in brachytherapy and high-intensity focused ultrasound ablation (HIFU).
• Performs radiofrequency ablation and proton-beam therapy for various malignancies.
• Treats pancreatic, breast, ovarian, and brain cancers using targeted radiation.
• Expert in nuclear medicine diagnostics, including PET-CT with Gallium 68.

Dr. Havva Asuman Yavuz is a nephrologist at Medical Park Antalya Hospital Complex. She completed a fellowship in critical care nephrology and transplantation at San Bortolo Hospital in Italy. Dr. Yavuz specializes in organ transplantation and complex kidney care. She works at the largest private hospital in the Mediterranean region.

• Member of the International Society of Nephrology and the European Society of Nephrology.
• Performs robotic nephrectomy using the Da Vinci surgical system.
• Treats chronic kidney disease, performing dialysis and kidney biopsies.
• Holds an Associate Professorship from Hacettepe University Faculty of Medicine.

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Dr. Nail Paksoy is an associate professor of medical oncology at Medipol Bahçelievler Hospital. He is board-certified by the European Society for Medical Oncology (ESMO). Dr. Paksoy specializes in lung, breast, and gastrointestinal cancers. He uses modern immunotherapy and targeted therapy protocols. His clinic is JCI-accredited for high safety standards.

• Served as a subinvestigator in over 8 international clinical trials for Roche and Pfizer.
• Authored over 40 research articles in journals indexed by SCI and SSCI.
• Completed dual fellowships in allergy-immunology and medical oncology.
• Treats complex sarcomas and renal cell carcinomas with systemic therapies.

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Mustafa Serkan Alemdar is a clinical oncologist at Medical Park Antalya Hospital Complex. He specializes in treating complex solid tumors and blood cancers. Dr. Alemdar completed his medical degree and oncology fellowship at Akdeniz University. He is an active member of the Turkish Society of Medical Oncology.

• Treats a wide range of cancers including breast, lung, and prostate.
• Expert in hematology-oncology for conditions like leukemia, myeloma, and lymphoma.
• Performs systemic therapies such as chemotherapy, immunotherapy, and targeted biological therapy.
• Works at a facility that houses specialized oncology-bone marrow units and LINAC technology.

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Dr. Amr Mahmoud Al Demery is a consultant thoracic surgical oncologist with 12 years of experience. He holds an M.B.B.Ch from Kasr El-Aini, Cairo University (2007). He earned a Master’s in Surgical Oncology in 2014 and a Doctorate in Surgical Oncology in 2019 from the National Cancer Institute, Cairo University. He is a Member of the Royal College of Surgeons of England (MRCS, 2014). He speaks English and Arabic.

His practice includes the assessment, diagnosis, and surgical treatment of thoracic cancers. He performs bronchoscopy, thoracoscopy, and mediastinoscopy. He carries out lung resections, including wedge resection, lobectomy, bilobectomy, and pneumonectomy. He also performs esophageal resection with reconstruction and pleural decortication. His work includes thymectomy and mediastinal lymph node dissection. He performs chest wall and diaphragmatic tumor resection with reconstruction.

He served as Resident, Assistant Lecturer, and Lecturer of Surgical Oncology at the National Cancer Institute, Cairo University. He is a consultant in thoracic surgical oncology at Dar El-Salam, Tanta, Damanhour, and Shefaa Al Orman Cancer Centers. He is a member of the Egyptian Society of Surgical Oncology. He is a cofounder and member of the Egyptian Society of Respiratory Neoplasms.

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.